STOCK TITAN

GeneDx Holdings Corp. - WGS STOCK NEWS

Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.

GeneDx Holdings Corp. (Nasdaq: WGS) is a leading company in the field of personalized genetic insights, aiming to revolutionize healthcare through genomic and clinical data. The company focuses on providing actionable health insights that help in accurate diagnosis, targeted treatment, and drug discovery. GeneDx is driven by its comprehensive data sets on rare diseases, enabling precision medicine to become a standard practice.

GeneDx operates primarily through two segments: GeneDx, which is the main revenue generator, and Legacy Sema4 diagnostics. The company is well-regarded for its exome and genome testing and has one of the world's most extensive rare disease datasets. Recent achievements include groundbreaking research on exome sequencing for epilepsy patients, which has shown superior clinical outcomes compared to multi-gene panels.

In the fourth quarter of 2023, GeneDx reported strong financial performance, with a significant increase in utilization of exome and genome products, higher reimbursement rates, and reduced cash burn. The company aims to achieve profitability by 2025. GeneDx continues to forge valuable partnerships, such as its collaboration with Komodo Health, to advance drug discovery and patient care.

GeneDx is also making strides in expanding access to its rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs) through a new collaboration with Epic. This integration will allow seamless data sharing between health systems and improve patient outcomes by speeding up the diagnosis and treatment process.

The company's participation in events like the World Orphan Drug Congress highlights its commitment to advancing precision medicine. With a focus on both clinical and biopharma partnerships, GeneDx is well-positioned to continue its growth and impact on the healthcare industry.

For more information, visit the GeneDx website and connect with them on social media platforms like LinkedIn, Facebook, and Instagram.

Rhea-AI Summary
GeneDx (WGS) to Participate in Cowen Healthcare Conference, Hosting Fireside Chat on March 6, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
-
Rhea-AI Summary
GeneDx Holdings Corp. (WGS) reported strong fourth quarter 2023 financial results with revenue of $58.1M, 68% growth in exome and genome test revenue, and adjusted gross margins of 56%. The company narrowed its adjusted net loss to $17.8M and reduced cash burn by 51% year-over-year. GeneDx issued guidance for FY 2024 revenue between $220M and $230M and aims for profitability in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.63%
Tags
-
Rhea-AI Summary
GeneDx (Nasdaq: WGS) will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024. The management will host a conference call to discuss 2023 financial and operating results and share full year 2024 guidance at 4:30 p.m. Eastern Time. Investors can register online to listen to the conference call and access the live and archived webcast on the GeneDx investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences earnings
Rhea-AI Summary
GeneDx announced the granting of 106,030 restricted stock units (RSUs) to newly hired employees as inducements, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, subject to continued service with the company. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.98%
Tags
none
-
Rhea-AI Summary
GeneDx Holdings Corp. (Nasdaq: WGS) expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57M, with at least 63% year-over-year revenue growth for exome and genome test revenue. The company reduced fourth quarter 2023 cash burn by 51% year-over-year and 21% sequentially, ending December 31, 2023, with a cash position of at least $131 million. GeneDx is reiterating the path to profitability in 2025, with a strong focus on improving health outcomes through genomic and clinical insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.36%
Tags
-
Rhea-AI Summary
GeneDx (Nasdaq: WGS) presents new data at the American Epilepsy Society (AES) annual meeting, showing exome sequencing offers superior clinical results compared to multi-gene panels for patients with epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
Rhea-AI Summary
GeneDx (Nasdaq: WGS) to Participate in Evercore ISI HealthCONx Conference, President and CEO to Speak at Fireside Chat
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences
-
Rhea-AI Summary
GeneDx (GDXX) Grants 10,000 RSUs to Newly Hired Employees Under 2023 Equity Inducement Plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

Boston Dynamics, a leader in mobile robotics, announced the launch of their new robot, Stretch, designed for warehouse automation. The robot is equipped with a smart gripper and advanced vision system, offering flexibility and efficiency in handling a wide range of products. With the increasing demand for e-commerce and logistics automation, Stretch is poised to revolutionize warehouse operations, reducing manual labor and increasing productivity. This innovative solution aligns with the company's commitment to advancing robotics technology and addressing evolving industry needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.95%
Tags
management
Rhea-AI Summary
GeneDx Holdings Corp. reported total revenue of $53M with over 40% YoY growth in exome and genome test revenue. Gross margins expanded to 48% in continuing operations and cash burn reduced by 52% YoY. The company secured a $75M debt facility and initiated a $40M cost savings plan. Updated guidance projects $187-$192M in FY 2023 revenue and profitability in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.34%
Tags

FAQ

What is the current stock price of GeneDx Holdings (WGS)?

The current stock price of GeneDx Holdings (WGS) is $72.07 as of November 21, 2024.

What is the market cap of GeneDx Holdings (WGS)?

The market cap of GeneDx Holdings (WGS) is approximately 2.0B.

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. provides personalized genetic insights to help diagnose, treat, and improve drug discovery through exome and genome testing.

What are GeneDx's main business segments?

GeneDx operates through two main segments: the GeneDx unit, which generates most of the revenue, and the Legacy Sema4 diagnostics unit.

What recent achievements has GeneDx made?

GeneDx recently published research showing the effectiveness of exome sequencing for epilepsy patients and reported strong financial performance for Q4 2023.

What partnerships does GeneDx have?

GeneDx has collaborated with Komodo Health to advance drug discovery and with Epic to expand its rapid whole genome sequencing services in NICUs.

What is the significance of GeneDx's exome and genome testing?

GeneDx's exome and genome testing help in accurate diagnosis, targeted treatment, and improved drug discovery, especially for rare diseases.

How is GeneDx impacting neonatal care?

GeneDx's collaboration with Epic enables rapid whole genome sequencing in NICUs, improving the diagnosis and treatment of critically ill infants.

When does GeneDx expect to achieve profitability?

GeneDx aims to reach profitability by 2025, supported by increased product utilization and higher reimbursement rates.

How extensive is GeneDx's rare disease data set?

GeneDx possesses one of the world's largest rare disease data sets, which is key to its precision medicine initiatives.

What events does GeneDx participate in?

GeneDx participates in events like the World Orphan Drug Congress to discuss advancements in precision medicine.

Where can I find more information about GeneDx?

You can visit the GeneDx website at www.genedx.com and follow them on LinkedIn, Facebook, and Instagram for the latest updates.

GeneDx Holdings Corp.

Nasdaq:WGS

WGS Rankings

WGS Stock Data

1.98B
22.09M
20.28%
70.21%
9.48%
Health Information Services
Services-health Services
Link
United States of America
STAMFORD